logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Dennis Dong Hwan Kim

Princess Margaret Cancer Centre
H指数:35
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cell Therapy Transplant Canada (CTTC) Consensus-Based Review for the Use of Supportive Care and Topical Therapies for Chronic Graft-Versus-Host Disease

细胞疗法移植加拿大（CTTC）关于慢性移植物抗宿主病支持性护理和局部疗法的共识性综述

Current Oncology
IF3.4
2026-09-100
OA
Kylie Lepic; Joseph Aziz; Gizelle Popradi; Christopher Lemieux; Jennifer White; Stephanie Maier; Mohamed Elemary; Kirk Schultz; Kristjan Paulson; Ram Vasudevan Nampoothiri; David Allan; Dennis Dong Hwan Kim
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors

ASC4OPT：在先前接受过两种或多种酪氨酸激酶抑制剂治疗的慢性髓性白血病慢性期患者中进行的阿西米尼治疗优化研究

Leukemia
IF13.4
2026-04-230
OAAI
Andreas Hochhaus; Philipp le Coutre; Dragana Milojkovic; Dennis Dong Hwan Kim; Soo Min Lim; Carolina Pavlovsky; Thanh Nguyen; Franck Emmanuel Nicolini; Beatriz Moiraghi; Sebastian Grosicki; Chi Dung Phu; Gabriel Etienne; Fernando Marco de Lucas; Rosa Maria Ayala Diaz; Massimo Breccia; Charles Chuah; Roberto Abi Rached; Himanshu Pokhriyal; Aswin IC; Peter Schuld; Virginia Pilipovic; Franz Alisch; Carla Maria Boquimpani
Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

异基因造血干细胞移植后复发的AML患者的突变谱变化

Bone Marrow Transplantation
IF5.2
2026-04-030
OAAI
Kristina Maas-Bauer; Thomas Meyer; Mehtap Yücel; Maria Garofalaki; Stefanie Koßmann; Francesca Biavasco; Memnon Lysandrou; Miguel Waterhouse; Tobias Feuchtinger; Dietmar Pfeifer; Florian Ingelfinger; Tobias Wertheimer; Justus Duyster; Jae Sook Ahn; Robert J. Soiffer; Jürgen Finke; Ralph Wäsch; Alexandros Spyridonidis; Dennis Dong Hwan Kim; Claudia Wehr; Robert Zeiser
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

HMGCLL1基因变异的不良预后影响可通过一线二代酪氨酸激酶抑制剂疗法在慢性髓系白血病患者中消除。

Leukemia
IF13.4
2026-03-300
PRE
Maria Agustina Perusini; Katia Pagnano; Carolina Pavlovsky; Daniela Žáčková; Jiří Mayer; Beatriz Moiraghi; Ana Ines Varela; Michele Bianchini; Ana Beatriz Pascoal Lopes; Gislaine Duarte; Carmino Antonio de Souza; Ivana Ježíšková; Anežka Kvetková; Tomáš Jurček; Hye Won Lee; Myung Hee Chang; Jessie J. F. Medeiros; Sagi Abelson; Dennis Dong Hwan Kim
Frailty as a prognostic factor in younger adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

脆弱是接受异基因造血细胞移植的年轻成人急性髓系白血病患者的预后因素

Transplantation and Cellular Therapy
IF4.4
2026-01-200
PRE
Sergio Rodriguez-Rodriguez; Maria Queralt Salas; Nihar Desai; Eshrak Al-Shaibani; Igor Novitzky-Basso; Ivan Pasic; Auro Viswabandya; Fotios V. Michelis; Jonas Mattsson; Dennis Dong Hwan Kim; Rajat Kumar; Tommy Alfaro Moya
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in ASC4FIRST

Asciminib在asc4首先在新诊断的慢性粒细胞白血病中表现出优异的疗效和安全性

Blood
IF23.1
2025-12-170
OAAI
Jorge E. Cortes; Timothy P. Hughes; Jianxiang Wang; Dong-Wook Kim; Dennis Dong Hwan Kim; Jiri Mayer; Yeow-Tee Goh; Philipp le Coutre; Gabriel Etienne; Inho Kim; David J. Andorsky; Felice Bombaci; Ghayas C. Issa; Naoto Takahashi; Shruti Kapoor; Rajendra Jinwal; Kamel Malek; Tracey McCulloch; Lillian Yau; Richard A. Larson
Eltrombopag in Treating Post-Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering

Eltrombopag在治疗异基因造血干细胞移植后血细胞减少症中的应用：早期药物减量策略的有效性、应答持久性及成本效益分析

EUROPEAN JOURNAL OF HAEMATOLOGY
IF2.3
2025-12-011
PRE
Al-Omari, Rawan; Nampoothiri, Ram Vasudevan; Sakhdari, Ali; Atenafu, Eshetu G.; Chiarello, Caden; Kim, Dennis D.; Law, Arjun; Pasic, Ivan; Novitzky-Basso, Igor; Viswabandya, Auro; Michelis, Fotios V.; Mattsson, Jonas; Kumar, Rajat
Herpes zoster frequency and adjuvanted recombinant zoster vaccination after allogeneic hematopoietic cell transplantation

带状疱疹频率及异基因造血细胞移植后的佐剂重组带状疱疹疫苗接种

Transplantation and Cellular Therapy
IF4.4
2025-10-280
PRE
Victoria G Hall; Caden Chiarello; Mats Remberger; Deepali Kumar; Ivan Pasic; Dennis Dong Hwan Kim; Rajat Kumar; Auro Viswabandya; Fotios V Michelis; Arjun Law; Armin Gerbitz; Sapna Humar; Wilson Lam; Igor Novitzky-Basso; Jonas Mattsson
Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival

真实世界中，关于重度预治疗且对糖皮质激素难治的慢性移植物抗宿主病患者接受belumosudil治疗的加拿大数据：治疗结局及无失败生存期的风险因素分析

Annals of Hematology
IF2.4
2025-10-250
OA
Sergio Rodriguez-Rodriguez; Nihar Desai; Christopher Lemieux; Keven Vachon; Kareem Jamani; Mohamed Elemary; Tommy Alfaro-Moya; Eshrak Al-Shaibani; Ivan Pasic; Igor Novitzky-Basso; Fotios Michelis; Auro Viswabandya; Rajat Kumar; Jonas Mattsson; Arjun Law; Sylvie Lachance; Dennis Dong Hwan Kim
Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis

能否超越骨髓清除性预处理（MAC）？一项在年龄小于65岁的异基因造血细胞移植患者中使用ATG-PTCy-CSA预防GVHD的MAC与减低强度预处理（RIC）的比较研究

British Journal of Haematology
IF3.8
2025-09-180
PRE
Ruah Alyamany; Ahmed Alnughmush; Mats Remberger; Arjun Datt Law; Wilson Lam; Dennis (Dong Hwan) Kim; Fotios V. Michelis; Ivan Pasic; Igor Novitzky-Basso; Armin Gerbitz; Rajat Kumar; Jonas Mattsson; Auro Viswabandya
Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment

内皮活化与应激指数（EASIX）作为预测鲁索利替尼治疗糖皮质激素难治性急性移植物抗宿主病的失败生物标志物

British Journal of Haematology
IF3.8
2025-09-140
OAAI
Sergio Rodriguez-Rodriguez; Nihar Desai; Carol Chen; Kareem Jamani; Catherine Sohier-Poirier; Christopher Lemieux; Jennifer White; Mohamed Elemary; Michael Kennah; Tommy Alfaro Moya; Eshrak Al-Shaibani; Igor Novitzky-Basso; Ivan Pasic; Arjun Datt Law; Fotios V. Michelis; Auro Viswabandya; Rajat Kumar; Jonas Mattsson; Dennis Dong Hwan Kim
A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation

使用ATG和PTCy预防匹配无关供者异基因造血细胞移植中移植物抗宿主病十年的经验

British Journal of Haematology
IF3.8
2025-08-270
PRE
Nihar Desai; Sergio Rodriguez-Rodriguez; Eshrak Al-Shaibani; Tommy Alfaro Moya; Arjun Datt Law; Igor Novitzky-Basso; Ivan Pasic; Fotios V. Michelis; Rajat Kumar; Dennis Dong Hwan Kim; Jonas Mattsson; Auro Viswabandya
Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation

异基因造血干细胞移植后，移植物抗宿主病预防措施对第二原发恶性肿瘤的影响

British Journal of Haematology
IF3.8
2025-07-190
PRE
Nihar Desai; Eshrak Al-Shaibani; Tommy Alfaro-Moya; Arjun D. Law; Wilson Lam; Mats Remberger; Ivan Pasic; Igor Novitzky-Basso; Auro Viswabandya; Dennis D. Kim; Rajat Kumar; Jeffrey H. Lipton; Jonas Mattsson; Fotios V. Michelis
Association of Cyclosporine Exposure Post-Allogeneic Hematopoietic Cell Transplant With Graft Failure and Relapse Risk in Hematological Malignancies

异基因造血细胞移植后环孢素暴露与血液系统恶性肿瘤中移植物失败和复发风险的关系

Transplantation and Cellular Therapy
IF4.4
2025-06-110
PRE
Ahmed Alnughmush; Mats Remberger; Vathany Kulasingam; Ivan Pasic; Igor Novitzky-Basso; Arjun D. Law; Wilson Lam; Dennis D. Kim; Armin Gerbitz; Rajat Kumar; Auro Viswabandya; Jonas Mattsson; Fotios V. Michelis
Conditioning Regimens for Second Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Graft Failure

自体骨髓移植失败患者进行第二次异基因造血干细胞移植的预处理方案

Transplantation and Cellular Therapy
IF4.4
2025-06-110
PRE
Nihar Desai; Sergio Rodriguez Rodriguez; Carol Chen; Eshetu G. Atenafu; Tommy Alfaro-Moya; Arjun Datt Law; Eshrak Al-Shaibani; Igor Novitzky-Basso; Ivan Pasic; Fotios V. Michelis; Auro Viswabandya; Dennis D. Kim; Jonas Mattsson; Rajat Kumar
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

Asciminib在ASCEMBL研究中经过近4年的随访后，在晚期慢性粒细胞白血病慢性期（CML-CP）中仍优于bosutinib。

Blood Advances
IF7.1
2025-05-090
OAAI
Michael J. Mauro; Yosuke Minami; Andreas Hochhaus; Elza Lomaia; Sergey Voloshin; Anna Turkina; Dong-Wook Kim; Jane F. Apperley; Jorge E. Cortes; Andre Abdo; Laura Maria Fogliatto; Dennis Dong Hwan Kim; Philipp le Coutre; Susanne Saussele; Mario Annunziata; Timothy P. Hughes; Naeem Chaudhri; Lynette Chee; Valentin García-Gutiérrez; Koji Sasaki; Carla Boquimpani; Shruti Kapoor; Noemi Espurz; Vishal Dhamal; Delphine Rea

研究方向

暂未获取到该数据
A
Arjun Law
H 指数:22论文数:269被引数:1,779
A
Auro Viswabandya
H 指数:34论文数:451被引数:4,620
F
Fotios V. Michelis
H 指数:23论文数:284被引数:2,106
R
Rajat Kumar
H 指数:28论文数:366被引数:3,884
J
Jonas Mattsson
H 指数:53论文数:538被引数:9,513
I
Igor Novitzky‐Basso
H 指数:18论文数:165被引数:2,295
I
Ivan Pašić
H 指数:16论文数:179被引数:941
W
Wilson Lam
H 指数:22论文数:337被引数:1,739
J
Jeffrey H. Lipton
H 指数:58论文数:732被引数:1.7万
A
Armin Gerbitz
H 指数:30论文数:215被引数:3,993